MarketCap
Facebook
X
Telegram
Atara Biotherapeutics Financial Ratios 2025-2011 | ATRA
Brief overview of Atara Biotherapeutics's market valuation
Current figures are compared with the company's own five-year history for 2018–2022.
Key multiples at the end of the period are P/S 0.61x (median 0.5x), P/B 4.1x (median 4.1x). Ratios sit near their own comparison base, with an average deviation of +10.7% from five-year medians.
Capital efficiency is characterized by ROE -84.9%, ROA 161.5%, ROCE -93.1%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
The cash cycle accelerated by 114.2 days to 4.1 days. Less capital is tied up in operations.
Valuation takeaway
Atara Biotherapeutics's profile looks neutral, with price and fundamental efficiency broadly aligned.
Annual Financial Ratios Atara Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
2.3 | -0.6 | -0.0 | -2.3 | -4.3 | -4.7 | -2.4 | -6.9 | -10.1 | -4.6 | -8.1 | -4.3 | - | - | - |
P/S |
0.6 | 0.4 | 0.3 | 8.2 | - | - | - | - | - | - | - | - | - | - | - |
EPS |
2.6 | -11.4 | -65.2 | -2.2 | -3.6 | -4.2 | -5.7 | -5.3 | -4 | -2.8 | - | - | - | - | - |
EV (Enterprise Value) |
124 M | 232 M | 242 M | 676 M | 1.56 B | 1.38 B | 676 M | 1.58 B | 1.16 B | 326 M | 449 M | 102 M | 11.2 M | 3.81 M | - |
EBITDA per Share |
3.03 | -10.5 | -64 | -2.69 | -3.53 | -4.07 | -5.63 | -5.33 | -4.04 | -2.81 | -2.28 | -5.65 | - | - | - |
EV/EBITDA |
3.3 | -3.0 | -0.9 | -2.5 | -4.5 | -3.9 | -2.2 | -6.5 | -9.3 | -3.9 | -7.5 | -3.5 | - | - | - |
PEG |
0.01 | -0.0 | -0.0 | 0.42 | -0.54 | -0.31 | 0.32 | 0.22 | 0.22 | 0.2 | -0.13 | 0.01 | - | - | - |
P/B |
-1.9 | -0.5 | -0.0 | 4.1 | 5.3 | 3.1 | 2.4 | 4.7 | 6.8 | 1.4 | 1.5 | 1.2 | - | - | - |
P/CF |
-1.4 | -0.7 | -0.0 | -1.9 | -6.7 | -8.0 | -2.9 | -7.3 | -11.2 | -5.8 | -12.4 | -7.3 | - | - | - |
ROE % |
-84.90 | 87.79 | -278.27 | -180.28 | -121.65 | -66.32 | -100.07 | -68.08 | -67.18 | -31.15 | -18.16 | -27.14 | - | - | - |
ROA % |
161.54 | -78.28 | -166.84 | -60.65 | -72.66 | -52.14 | -84.85 | -58.88 | -54.87 | -29.95 | -17.61 | -26.39 | - | - | - |
ROCE % |
-93.14 | 85.77 | -278.14 | -221.50 | -121.76 | -66.85 | -96.56 | -67.39 | -63.92 | -31.95 | -18.54 | -27.23 | - | - | - |
Current Ratio |
0.3 | 0.5 | 0.6 | 1.5 | 2.5 | 4.7 | 7.4 | 8.0 | 6.2 | 26.9 | 33.4 | 38.9 | - | - | - |
DSO |
4.1 | 50.4 | 1582.3 | 118.3 | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
4.1 | 50.4 | 1582.3 | 118.3 | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
4.1 | 50.4 | 1582.3 | 118.3 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Atara Biotherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.2 | -0.29 | - | -0.32 | 0.2 | 3.53 | - | -2.93 | -3.1 | -5.65 | - | -16.4 | -16.91 | -0.72 | - | -0.82 | 0.18 | -0.87 | - | -0.9 | -0.91 | -0.86 | - | -0.92 | -1.14 | -1.2 | - | -1.31 | -1.6 | -1.44 | - | -1.29 | -1.15 | -1.05 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.26 | -0.24 | - | - | - | 3.77 | - | -2.83 | -2.85 | -5.31 | - | -16.1 | -16.8 | -0.71 | - | -0.82 | -0.3 | -0.86 | - | -0.88 | -0.89 | -0.83 | - | -0.89 | -1.12 | -1.19 | - | -1.29 | -1.59 | -1.44 | - | -1.3 | -1.17 | -1.06 | - | -1.03 | -0.95 | -0.89 | - | -0.9 | -0.68 | -0.6 | - | -0.44 | -0.62 | -0.42 | - | - | -3.39 | -5.6 | - | -2.61 | - | - | -5.58 | - | - | - | - | - | - | - |
ROE % |
13.59 | -52.98 | -64.08 | -39.89 | -34.45 | 4.66 | 73.68 | 210.97 | -767.18 | -899.47 | -931.77 | -976.71 | -1106.83 | -192.15 | -77.05 | -104.35 | -84.68 | -111.48 | -72.20 | -88.28 | -77.74 | -68.36 | -48.73 | -73.46 | -82.94 | -88.97 | -73.07 | -90.30 | -80.59 | -67.26 | -44.47 | -61.95 | -60.15 | -59.56 | -47.33 | -57.33 | -47.28 | -38.39 | -23.97 | -27.73 | -22.48 | -17.94 | -11.42 | -17.15 | -17.76 | -19.85 | -16.94 | 6.08 | 122.09 | -6.83 | - | 23.02 | - | - | 110.28 | - | - | - | - | - | - | - |
ROA % |
-16.73 | 32.75 | 53.47 | 38.12 | 36.14 | 10.46 | -50.81 | -87.78 | -101.28 | -109.79 | -90.58 | -113.41 | -72.20 | -65.53 | -40.77 | -59.59 | -55.10 | -74.13 | -51.95 | -64.59 | -58.95 | -53.10 | -38.31 | -59.27 | -68.31 | -74.46 | -61.96 | -76.85 | -68.87 | -57.78 | -38.46 | -52.74 | -50.44 | -49.23 | -38.65 | -48.27 | -41.14 | -34.82 | -23.04 | -26.70 | -21.68 | -17.34 | -11.07 | -16.65 | -17.25 | -19.29 | -16.47 | -21.36 | -4.25 | -6.64 | - | -4.89 | - | - | - | - | - | - | - | - | - | - |
ROCE % |
6.38 | -60.80 | -69.82 | -45.79 | -39.11 | 1.80 | 72.26 | 209.19 | -772.91 | -904.83 | -936.62 | -981.84 | -1131.25 | -212.52 | -97.03 | -124.38 | -104.49 | -111.62 | -72.29 | -88.45 | -77.96 | -68.78 | -49.17 | -74.13 | -83.95 | -90.43 | -74.28 | -91.40 | -81.40 | -67.49 | -44.15 | -60.80 | -58.36 | -57.16 | -45.09 | -55.29 | -46.31 | -38.34 | -24.58 | -28.47 | -23.06 | -18.34 | -11.63 | -17.40 | -17.91 | -19.97 | -17.02 | 6.15 | 121.73 | -6.86 | - | 23.16 | - | - | 109.82 | - | - | - | - | - | - | - |
Current Ratio |
0.3 | 0.3 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.8 | 1.0 | 1.3 | 1.5 | 2.0 | 2.4 | 2.3 | 2.5 | 3.2 | 3.6 | 4.1 | 4.7 | 4.7 | 4.7 | 4.7 | 6.6 | 6.6 | 6.6 | 6.6 | 7.4 | 7.4 | 7.4 | 7.4 | 5.5 | 5.5 | 5.5 | 5.5 | 25.9 | 25.9 | 25.9 | 25.9 | 32.9 | 32.9 | 32.9 | 32.9 | 36.1 | 36.1 | 36.1 | 36.1 | 29.6 | 29.6 | - | - | - | - | - | - | - | - | - | - |
DSO |
3.2 | 131.0 | - | 25.3 | 23.0 | 4.8 | - | 4.3 | 60.9 | 116.7 | - | 14.3 | 43.1 | 1511.6 | - | 9.1 | 1.1 | 10.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | 4.8 | - | 4.3 | 60.9 | 116.7 | - | 14.3 | 43.1 | 1511.6 | - | 9.1 | 1.1 | 10.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | 4.8 | - | 4.3 | 60.9 | 116.7 | - | 14.3 | 43.1 | 1511.6 | - | 9.1 | 1.1 | 10.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Atara Biotherapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
